Drug class
Recombinant Erwinia chrysanthemi L-asparaginase; antineoplastic enzyme
Mechanism of action
Catalyses hydrolysis of circulating L-asparagine to L-aspartic acid and ammonia. Depletion of extracellular asparagine limits protein synthesis and survival of leukaemic lymphoblasts that have low asparagine-synthetase capacity.
General use cases
- As a component of multi-agent chemotherapy for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in adults and children aged 1 month and older who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
